Sweden's CLS Q1 sales fall 72% after partner talks

Clinical Laserthermia Systems AB

12/05/2026 07:42

Overview

Sweden cancer therapy device maker's Q1 sales fell 72% yr/yr due to partner alignment talks

Q1 operating profit declined, reflecting lower revenue, not higher expenses

Company secured SEK 23 mln purchase orders for Prism business after quarter end

Outlook

CLS expects 2026 revenue to show strong double-digit growth versus 2025, with H2 weighting

Company has secured purchase orders of about SEK 23 mln for the neurosurgery Prism business

CLS now expects positive cash flow from Q1 2028, updating previous guidance of Q4 2026

Result Drivers

PARTNER ALIGNMENT TALKS - Sales of Prism products to neurosurgery partner were temporarily impacted by ongoing alignment discussions, leading to lower Q1 revenue

CLINICAL MOMENTUM - Continued installations and procedure growth in U.S. neurosurgery market reflected underlying clinical and commercial momentum

COST CONTROL - Decline in operating profit reflected lower revenue, not increased expenses, as CLS maintained strict cost control and improved operational efficiency

Company press release: ID:nWkr5SxJgY

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 1.30 mln


Analyst Coverage

Wall Street's median 12-month price target for Clinical Laserthermia Systems AB is SEK9.00, about 86.3% above its May 11 closing price of SEK4.83

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)